ea0084ps2-07-57 | Graves’ Disease 1 | ETA2022
Popescu Veronica
, Beirinckx Annemie
, Decallonne Brigitte
Objectives: Graves hyperthyroidism is a frequent complication of alemtuzumab treatment in MS. We present the case of an MS patient who developed clinically and biochemically overt alemtuzumab-induced Graves disease, remitting 6 months after treatment with ocrelizumab and methylprednisolone pulse-therapy.Methods: A 49-year-old man diagnosed with active multiple sclerosis who had undergone alemtuzumab treatment, and developed Graves hyper...